Drug
SEP-363856 clinical trials
Also written SEP-363856 and Ulotaront.
Keep track of what changes. Save the SEP-363856 studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
30 studies that test it; most in 2022 (6)
| Year | Studies |
|---|---|
| 2013 | 1 |
| 2014 | 2 |
| 2016 | 2 |
| 2017 | 2 |
| 2019 | 5 |
| 2020 | 2 |
| 2021 | 2 |
| 2022 | 6 |
| 2023 | 3 |
| 2025 | 2 |
| 2026 | 3 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 30 · Other 0
Otsuka Pharmaceutical Development & Commercialization, Inc. (25) · Sumitomo Pharma Co., Ltd. (4) · Otsuka Pharmaceutical Co., Ltd. (1)
Studies
Open first, then newest update. How each study uses SEP-363856 is read from its arms, and is right about nine times in ten.
Testing it · 30
- A Trial of the Efficacy and Safety of Fixed Doses of SEP-363856 in Adults With Generalized Anxiety DisorderRecruitingPhase 3Otsuka Pharmaceutical Development & Commercialization, Inc.NCT07759128Written as SEP-363856
- A Trial of the Efficacy and Safety of a Fixed Dose of SEP-363856 in Adults With Generalized Anxiety DisorderRecruitingPhase 3Otsuka Pharmaceutical Development & Commercialization, Inc.NCT07767903Written as SEP-363856
- A Trial of the Safety and Tolerability of SEP-363856 in Adults With Generalized Anxiety DisorderRecruitingPhase 3Otsuka Pharmaceutical Development & Commercialization, Inc.NCT07786454Written as SEP-363856
- A Long-term Administration Trial of SEP-363856 in Patients With SchizophreniaRecruitingPhase 3Otsuka Pharmaceutical Co., Ltd.NCT07225712Written as SEP-363856
- A Trial of the Efficacy and Safety of SEP-363856 in Acutely Psychotic Participants With SchizophreniaActive, not recruitingPhase 3Otsuka Pharmaceutical Development & Commercialization, Inc.NCT06894212Written as SEP-363856
- A Clinical Trial That Will Study the Efficacy and Safety of an Investigational Drug in Acutely Psychotic People With SchizophreniaCompletedPhase 3Otsuka Pharmaceutical Development & Commercialization, Inc.NCT04092686Written as SEP-363856 75mg
- A Clinical Trial to Study the Efficacy and Safety of an Investigational Drug in Acutely Psychotic People With SchizophreniaCompletedPhase 3Otsuka Pharmaceutical Development & Commercialization, Inc.NCT04072354Written as SEP-363856 50mg
- A Trial of the Safety and Efficacy of SEP-363856 in the Treatment of Adults With Major Depressive DisorderCompletedPhase 2Otsuka Pharmaceutical Development & Commercialization, Inc.NCT05593029Written as SEP-363856
- A Study of the Long-term Safety and Tolerability of an Investigational Drug in People With Schizophrenia.CompletedPhase 3Otsuka Pharmaceutical Development & Commercialization, Inc.NCT04115319Written as SEP363856
- A Clinical Study That Will Evaluate How Well SEP-363856 Works and How Safe it is in People With Schizophrenia That Switch to SEP-363856 From Their Current Antipsychotic MedicationCompletedPhase 3Otsuka Pharmaceutical Development & Commercialization, Inc.NCT05628103Written as SEP-363856
- An Extension Study to a Clinical Study That Will Continue to Evaluate the Effectiveness and Safety of SEP-363856 in People With Schizophrenia That Switch to SEP-363856 From Their From Their Current Antipsychotic MedicationCompletedPhase 3Otsuka Pharmaceutical Development & Commercialization, Inc.NCT05741528Written as SEP-363856
- A Clinical Study That Will Measure How Well SEP-363856 Works and How Safe it is in Adults With Generalized Anxiety DisorderCompletedPhase 2/3Otsuka Pharmaceutical Development & Commercialization, Inc.NCT05729373Written as SEP-363856
- A Clinical Trial to Evaluate the Long-term Safety and Tolerability of SEP-363856 in Patients With Schizophrenia in JapanTerminatedPhase 3Sumitomo Pharma Co., Ltd.NCT05359081Written as SEP-363856
- A Clinical Study to Investigate the Effect of an Investigational Drug as an Added Medication to an Antipsychotic, in Adults With Schizophrenia, as Measured Positron Emission Tomography (PET) ImagingCompletedPhase 1Otsuka Pharmaceutical Development & Commercialization, Inc.NCT04038957Written as SEP-363856
- A Clinical Study to Evaluate the Long-term Safety and Tolerability of an Investigational Drug in People With SchizophreniaTerminatedPhase 3Otsuka Pharmaceutical Development & Commercialization, Inc.NCT04109950Written as SEP-363856
- A Study to Evaluate the Efficacy and Safety of SEP-363856 in Acutely Psychotic Adults With SchizophreniaCompletedPhase 2Otsuka Pharmaceutical Development & Commercialization, Inc.NCT02969382Written as SEP-363856
- An Extension Study of Safety and Tolerability of SEP-363856 in Adult Subjects With SchizophreniaCompletedPhase 2Otsuka Pharmaceutical Development & Commercialization, Inc.NCT02970929Written as SEP-363856
- A Study to Evaluate the Efficacy, Safety and Tolerability of SEP-363856 in Subjects With Parkinson's Disease PsychosisCompletedPhase 2Otsuka Pharmaceutical Development & Commercialization, Inc.NCT02969369Written as SEP-363856
- Study Assessing the Safety, Tolerability, and Pharmacokinetics of SEP-363856 in Male and Female Subjects With SchizophreniaCompletedPhase 1Otsuka Pharmaceutical Development & Commercialization, Inc.NCT01994473Written as SEP-363856
- This is a Study to Determine the Effect of Multiple Doses of an Investigational Drug, Taken by Mouth, in People With Narcolepsy-cataplexy. Accepting Both Males and Females Ages of 18 Years to 55 Years. This Study Will be Conducted in the US and Will Require Approximately 13 Weeks Participation.CompletedPhase 1Otsuka Pharmaceutical Development & Commercialization, Inc.NCT05015673Written as SEP363856
See all 30 studies that test SEP-363856 →
As the comparator · 1 — what is tested is compared with SEP-363856
Codes
What other systems call SEP-363856 · ClinicalTrials.gg INT001284
- MeSH (NLM) C000705647SEP-363856One source ClinicalTrials.gov
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000705647 | SEP-363856 | One source ClinicalTrials.gov |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.